Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive source : Ir.akerotx.com save search
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
Published: 2023-03-29 (Crawled : 20:00) - ir.akerotx.com
AKRO | $21.0 1.01% 1.09% 560K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -6.62%
fda positive efruxifermin meeting program therapeutics nash
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
Published: 2021-03-22 (Crawled : 20:00) - ir.akerotx.com
AKRO | $21.0 1.01% 1.09% 560K
|
Health Technology
|
| O: -0.67%
H: 1.38%
C: -3.0%
positive nash
Akero Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy
Published: 2020-11-13 (Crawled : 15:25) - ir.akerotx.com
AKRO | $21.0 1.01% 1.09% 560K
|
Health Technology
|
| O: 6.86%
H: 0.0%
C: -9.97%
phase 2 positive therapy efruxifermin nash potential phase 2b
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.